171 related articles for article (PubMed ID: 25340731)
1. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
[TBL] [Abstract][Full Text] [Related]
2. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
3. Clinical Significance of ABCG2 Haplotype-tagging Single Nucleotide Polymorphisms in Patients With Unresectable Non-Small Cell Lung Cancer Treated With First-line Platinum-based Chemotherapy.
Kim SH; Kim MJ; Cho YJ; Jeong YY; Kim HC; Lee JD; Hwang YS; Kim IS; Lee S; Oh SY; Ling H; Lee GW
Am J Clin Oncol; 2015 Jun; 38(3):294-9. PubMed ID: 23689644
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer.
Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA
J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer.
Yoshimura N; Kudoh S; Kimura T; Mitsuoka S; Kyoh S; Tochino Y; Asai K; Kodama T; Ichimaru Y; Yana T; Hirata K
J Thorac Oncol; 2009 Mar; 4(3):371-5. PubMed ID: 19155998
[TBL] [Abstract][Full Text] [Related]
6. SNPs and taxane toxicity in breast cancer patients.
Bosó V; Herrero MJ; Santaballa A; Palomar L; Megias JE; de la Cueva H; Rojas L; Marqués MR; Poveda JL; Montalar J; Aliño SF
Pharmacogenomics; 2014; 15(15):1845-58. PubMed ID: 25495407
[TBL] [Abstract][Full Text] [Related]
7. ABCB1 c.3435C>T polymorphism is associated with platinum toxicity: a preliminary study.
De Troia B; Dalu D; Filipazzi V; Isabella L; Tosca N; Ferrario S; Gambaro AR; Somma L; Fasola C; Cheli S; Clementi E; De Francesco D; Falvella FS; Cattaneo MT
Cancer Chemother Pharmacol; 2019 Apr; 83(4):803-808. PubMed ID: 30796464
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetics of the DNA repair pathways in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Sullivan I; Salazar J; Majem M; Pallarés C; Del Río E; Páez D; Baiget M; Barnadas A
Cancer Lett; 2014 Oct; 353(2):160-6. PubMed ID: 25069034
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of carboplatin-paclitaxel combination chemotherapy in elderly patients with advanced non-small cell lung cancer.
Okamoto I; Moriyama E; Fujii S; Kishi H; Nomura M; Goto E; Kiyofuji C; Imamura F; Mori T; Matsumoto M
Jpn J Clin Oncol; 2005 Apr; 35(4):188-94. PubMed ID: 15845567
[TBL] [Abstract][Full Text] [Related]
10. Associations of polymorphisms in DNA repair genes and MDR1 gene with chemotherapy response and survival of non-small cell lung cancer.
Du Y; Su T; Zhao L; Tan X; Chang W; Zhang H; Cao G
PLoS One; 2014; 9(6):e99843. PubMed ID: 24933103
[TBL] [Abstract][Full Text] [Related]
11. Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).
Joerger M; von Pawel J; Kraff S; Fischer JR; Eberhardt W; Gauler TC; Mueller L; Reinmuth N; Reck M; Kimmich M; Mayer F; Kopp HG; Behringer DM; Ko YD; Hilger RA; Roessler M; Kloft C; Henrich A; Moritz B; Miller MC; Salamone SJ; Jaehde U
Ann Oncol; 2016 Oct; 27(10):1895-902. PubMed ID: 27502710
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of paclitaxel as a 3-hour infusion followed by carboplatin in untreated patients with stage IV non-small cell lung cancer.
Rowinsky EK; Flood WA; Sartorius SE; Bowling MK; Wagner J; Ettinger DS
Semin Oncol; 1995 Aug; 22(4 Suppl 9):48-54. PubMed ID: 7644928
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase III PITCAP trial and meta-analysis of induction chemotherapy followed by thoracic irradiation with or without concurrent taxane-based chemotherapy in locally advanced NSCLC.
Ardizzoni A; Tiseo M; Boni L; Di Maio M; Buffoni L; Belvedere O; Grossi F; D'Alessandro V; de Marinis F; Barbera S; Caroti C; Favaretto A; Cortinovis D; Morrica B; Tixi L; Ceschia T; Parisi S; Ricardi U; Grimaldi A; Loreggian L; Navarria P; Huber RM; Belani C; Brunsvig PF; Scagliotti GV; Scolaro T
Lung Cancer; 2016 Oct; 100():30-37. PubMed ID: 27597278
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of combination chemotherapy with docetaxel and carboplatin for elderly patients with advanced non-small cell lung cancer.
Kim HJ; Kim TG; Lee HJ; Kim JH; Lim BH; Seo JW; Kang EM; Lee BU; Ahn YM; Roh YH; Nam SH; Kim BS
Lung Cancer; 2010 May; 68(2):248-52. PubMed ID: 19647333
[TBL] [Abstract][Full Text] [Related]
15. Paclitacxel and carboplatin in advanced non-small-cell lung cancer.
Huang PW; Gu YH; Lu KH; Shu YQ
Biomed Pharmacother; 2006 Dec; 60(10):698-700. PubMed ID: 17071050
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
Park HS; Lim SM; Shin HJ; Cho A; Shin JG; Lee MG; Kim HR; Kim JH; Cho BC
Pharmacogenet Genomics; 2016 Mar; 26(3):116-25. PubMed ID: 26641474
[TBL] [Abstract][Full Text] [Related]
17. RB1 polymorphism contributes to the efficacy of platinum-taxanes in advanced squamous cell lung cancer.
Liu D; Xu W; Zhang ZW; Qian J; Zheng H; Zhang J; Su B
Asian Pac J Cancer Prev; 2015; 16(2):775-81. PubMed ID: 25684524
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer.
Ishimoto O; Sugawara S; Inoue A; Ishida T; Munakata M; Koinumaru S; Hasegawa Y; Suzuki T; Miki H; Saijo Y; Nukiwa T
J Thorac Oncol; 2006 Nov; 1(9):979-83. PubMed ID: 17409982
[TBL] [Abstract][Full Text] [Related]
19. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.
Zhong J; Guo Z; Fan L; Zhao X; Zhao B; Cao Z; Cheng L; Shi Y; Li X; Zhang Y; An T; Wu M; Wang Y; Zhuo M; Li J; Yang X; Chen H; Jia B; Zhao J
Thorac Cancer; 2019 Nov; 10(11):2088-2095. PubMed ID: 31571407
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel plus carboplatin in the treatment of patients with advanced lung cancer: a Vanderbilt University Cancer Center phase II trial (LUN-46).
Johnson DH; Paul DM; Hande KR; DeVore R
Semin Oncol; 1996 Dec; 23(6 Suppl 16):42-6. PubMed ID: 9007120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
